Soluble CD163 is a biomarker for accelerated atherosclerosis in systemic lupus erythematosus patients at apparent low risk for cardiovascular disease

Objective: This study aimed to determine whether sCD163, a soluble macrophage marker up-regulated in numerous inflammatory disorders, is predictive of accelerated atherosclerosis associated with systemic lupus erythematosus (SLE). Methods: Carotid ultrasound was prospectively performed, at baseline...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of rheumatology 2020-01, Vol.49 (1), p.33-37
Main Authors: David, C, Divard, G, Abbas, R, Escoubet, B, Chezel, J, Chauveheid, MP, Rouzaud, D, Boutten, A, Papo, T, Dehoux, M, Sacre, K
Format: Article
Language:English
Subjects:
Adult
Antigens, CD - blood
Antigens, Differentiation, Myelomonocytic - blood
Biomarkers - blood
Cardiovascular Diseases - blood
Cardiovascular Diseases - etiology
Carotid Arteries - diagnostic imaging
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Lupus Erythematosus, Systemic - blood
Lupus Erythematosus, Systemic - complications
Male
Plaque, Atherosclerotic - blood
Plaque, Atherosclerotic - etiology
Receptors, Cell Surface - blood
Retrospective Studies
Risk Factors
ROC Curve
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: This study aimed to determine whether sCD163, a soluble macrophage marker up-regulated in numerous inflammatory disorders, is predictive of accelerated atherosclerosis associated with systemic lupus erythematosus (SLE). Methods: Carotid ultrasound was prospectively performed, at baseline and during follow-up, in 63 consecutive SLE patients asymptomatic for cardiovascular disease (CVD) and 18 volunteer health workers. Serum sCD163 level was determined at baseline using enzyme-linked immunosorbent assay. The primary outcome was the presence of a carotid plaque. Factors associated with carotid plaques were identified through multivariate analysis. Results: Despite a low risk for cardiovascular events according to Framingham score in both groups (2.1 ± 3.8% in SLE vs 2.1 ± 2.9% in controls; p = 0.416), ultrasound at baseline showed a carotid plaque in 23 SLE patients (36.5%) and two controls (11.1%) (p = 0.039). Multivariate analysis showed that SLE status increased the risk for carotid plaque by a factor of 9 (p = 0.017). In SLE patients, sCD163 level was high (483.7 ± 260.8 ng/mL vs 282.1 ± 97.5 ng/mL in controls; p
ISSN:0300-9742
1502-7732
DOI:10.1080/03009742.2019.1614213